EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 19.11.2024
M1 Kliniken AG increases operating profit (EBIT) by 71% in the first nine months of 2024 and confirms medium-term targets
Group: sales +8.7% to EUR 257.22 million and EBIT +70.7% to EUR 22.09 million
Beauty segment growth driver with sales +33.5% to EUR 71.02 million
EBIT in the Beauty segment +30.4% to EUR 16.26 million
Medium-term target c...
Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH
06.09.2024 / 14:30 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude ...
Operating Profit (EBIT) almost doubled: M1 Kliniken AG also grows significantly in the first half of 2024
Group: sales +11.2% to EUR 167.7 million and EBIT +98.8% to EUR 14.5 million
Earnings per share increased from EUR 0.17 to EUR 0.53
Beauty segment: sales +30.6% and EBIT +24.3%
Profitable growth to be continued
Berlin, 03.09.2024 –...
M1 Kliniken AG: Management Board confirms growth targets
Berlin, 21 June 2024 - As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG (ISIN: DE000A0STSQ8) for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.
Attila Strauss emphasis...
M1 Kliniken AG: Management Board confirms growth targets
Berlin, 21 June 2024 - As announced on 20 June 2024, Management Board member Attila Strauss has sold part of his stake in M1 Kliniken AG (ISIN: DE000A0STSQ8) for personal financial reasons. Mr Strauss continues to hold a tangible stake of over 2.3% in M1 Kliniken AG.
Attila Strauss emphasis...
M1 Kliniken announces change in the Management Board and confirms long-term growth strategy
Berlin, 11 June 2024 - Kilian Brenske, member of the Management Board since 2022, has asked the Supervisory Board to terminate his position on the Management Board for private reasons. The areas of national and international expansion, marketing, purchasin...
Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to M1 Kliniken AG
Company Name: M1 Kliniken AG
ISIN: DE000A0STSQ8
Reason for the research: Mid-term Guide & 2023 report & Q1 KPIs
Recommendation: Kaufen
from: 06.06.2024
Target price: €28
Target price on sight of: ...
Original-Research: M1 Kliniken AG - from First Berlin Equity Research GmbH
Classification of First Berlin Equity Research GmbH to M1 Kliniken AG
Company Name: M1 Kliniken AG
ISIN: DE000A0STSQ8
Reason for the research: Mid-term Guide & 2023 report & Q1 KPIs
Recommendation: Kaufen
from: 06.06.2024
Target price: €28
Target price on sight of: ...
M1 Kliniken AG on a growth path with cutting-edge medicine: EBIT +70% in the first quarter of 2024
Group sales increase by 9.6% to EUR 84.7 million in Q1 2024
Growth driver Beauty segment: sales +18.2% and EBIT +50%
Strong operating performance should continue for the rest of the year
Berlin, June 6, 2024 – M1 Kliniken AG (ISIN: DE000A...
M1 Kliniken AG on a growth path with cutting-edge medicine: EBIT +70% in the first quarter of 2024
Group sales increase by 9.6% to EUR 84.7 million in Q1 2024
Growth driver Beauty segment: sales +18.2% and EBIT +50%
Strong operating performance should continue for the rest of the year
Berlin, June 6, 2024 – M1 Kliniken AG (ISIN: DE000A...
You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .